During the last session, Arcus Biosciences Inc (NYSE:RCUS)’s traded shares were 0.51 million, with the beta value of the company hitting 0.91. At the end of the trading day, the stock’s price was $15.55, reflecting an intraday gain of 5.57% or $0.82. The 52-week high for the RCUS share is $25.47, that puts it down -63.79 from that peak though still a striking 16.72% gain since the share price plummeted to a 52-week low of $12.95. The company’s market capitalization is $1.41B, and the average trade volume was 817.71K shares over the past three months.
Arcus Biosciences Inc (NYSE:RCUS) trade information
Arcus Biosciences Inc (RCUS) registered a 5.57% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.57% in intraday trading to $15.55, hitting a weekly high. The stock’s 5-day price performance is 6.58%, and it has moved by -14.61% in 30 days. Based on these gigs, the overall price performance for the year is -13.56%.
Arcus Biosciences Inc (RCUS) estimates and forecasts
Statistics show that Arcus Biosciences Inc has outperformed its competitors in share price, compared to the industry in which it operates. Arcus Biosciences Inc (RCUS) shares have gone down -0.70% during the last six months, with a year-to-date growth rate more than the industry average at 13.49% against 12.90. In the rating firms’ projections, revenue will increase 63.80% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 35.56M as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 29.7M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 25M and 30.3M respectively. In this case, analysts expect current quarter sales to grow by 42.20% and then drop by -2.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -23.70%. While earnings are projected to return 8.38% in 2024.
RCUS Dividends
Arcus Biosciences Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
